TheStreet.com  Mar 18  Comment 
NEW YORK (TheStreet) -- Shares of Regeneron Pharmaceuticals  fell slightly, down 0.84% to $463.87, on Wednesday after the stock ran earlier in the week thanks to cholesterol drug data. The stock had been climbing this week after the company...
Market Intelligence Center  Mar 13  Comment 
For a hedged play on Regeneron Pharmaceuticals Inc (REGN) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a May. '15 $425.00 covered call for a net debit in the $402.56 area. That is also the break-even stock price for...
Market Intelligence Center  Mar 11  Comment 
After closing Tuesday at $422.84, Regeneron Pharmaceuticals Inc (REGN) presents an attractive opportunity to get a 5.68% return in just 65 days, which is an annualized return of 31.87% (for comparison purposes only). To enter this trade, sell one...
Benzinga  Feb 17  Comment 
Analysts at Bernstein initiated coverage on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) with a Outperform rating. The target price for Regeneron Pharmaceuticals is set to $475. Regeneron Pharmaceuticals' shares closed at $402.40 on...
Benzinga  Feb 17  Comment 
Analysts at Bernstein initiated coverage on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) with a Outperform rating. The target price for Regeneron Pharmaceuticals is set to $475. Regeneron Pharmaceuticals shares have gained 20.92% over the...
Jutia Group  Feb 13  Comment 
[PR Newswire] - TARRYTOWN, N.Y., Feb. 13, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: 2015 RBC Capital Markets' Global ... Read more on this. ...
Benzinga  Feb 11  Comment 
Morgan Stanley on Wednesday issued a report on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) after the company reported guidance that was below estimates. Regeneron is currently rated as Overweight with a price target of $499.00. Analysts Matthew...
Motley Fool  Feb 10  Comment 
Regeneron reported its fourth-quarter and full-year numbers this morning. Here's what investors need to know.


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki